Compliance with pregnancy prevention measures during isotretinoin therapy. Journal Article

Local Library Link: Find It @ Loyola

Authors: Collins, MK; Moreau, JF; Opel, D; Swan, J; Prevost, N; Hastings, M; Bimla Schwarz, E; Korb Ferris, L
Article Title: Compliance with pregnancy prevention measures during isotretinoin therapy.
Abstract: BACKGROUND: Approximately 150 women annually become pregnant while taking isotretinoin despite participation in the iPLEDGE program. Noncompliance with the requirement to be abstinent or use 2 contraceptive methods may be a contributing factor. OBJECTIVE: We sought to determine the degree of adherence to contraception or abstinence among women taking isotretinoin. METHODS: We conducted an anonymous survey of women of childbearing potential taking isotretinoin for at least 2 months. RESULTS: Among 75 participants, 21 (28%) chose abstinence as their primary means of pregnancy prevention, of whom 4 (19%) were sexually active during treatment. The most commonly chosen contraceptive methods among the 39 women who were sexually active were condoms (35, 90%) and oral contraceptive pills (18, 46%). Twelve women (31%) admitted to having intercourse at least once using 1 or fewer forms of contraception; 10 failed to use condoms, and 1 reported completely unprotected intercourse. Among sexually active oral contraceptive pill users, 7 (39%) reported missing 1 or more pills in the previous month. LIMITATIONS: Data were self-reported, thus participants may have inaccurately reported contraception use. CONCLUSIONS: Encouraging the use of highly effective, patient-independent contraception and limiting abstinence to women who have never been sexually active may further reduce the rate of isotretinoin-exposed pregnancies.
Journal Title: Journal of the American Academy of Dermatology
ISSN: 1097-6787; 0190-9622
Publisher: Unknown  
Date Published: 2014